Liminatus Pharma, Inc.
LIMN
$14.43
$1.6312.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | 03/31/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | -- | 167.00K | -- | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | 300.00 | -- | 200.00 | ||
| Total Operating Expenses | 300.00 | 167.00K | 200.00 | ||
| Operating Income | -300.00 | -167.00K | -200.00 | ||
| Income Before Tax | -300.00 | -229.00K | -200.00 | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -300.00 | -229.00K | -200.00 | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -300.00 | -229.00K | -200.00 | ||
| EBIT | -300.00 | -167.00K | -200.00 | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | 0.00 | 0.00 | 0.00 | ||
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | ||
| EPS Diluted | 0.00 | 0.00 | 0.00 | ||
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | ||
| Average Basic Shares Outstanding | 26.01M | 112.22M | 112.22M | ||
| Average Diluted Shares Outstanding | 26.01M | 112.22M | 112.22M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||